The evidence changes when the body part changes

Tendon studies give clearer yes and no answers

For a sore elbow tendon, cortisone helped more during the first two months. PRP did better from about six months in the studies being compared. That's a later result, not quick relief, and some heel and outer-hip tendon studies also found later gains over cortisone.

Other tendons had different results. PRP did no better than salt water for the Achilles tendon, and the same was true for ankle arthritis. An elbow result can't tell you what will happen in a knee.

Simple care still matters while you weigh a procedure

Easy exercise can keep the joint moving while physical therapy builds nearby strength. Warmth may loosen stiffness, and a cold pack may calm swelling. A brace or well-fitting shoes can reduce strain, and these steps aren't flashy, but they may help your day.

Pain medicine needs care when your kidneys, stomach, or heart already have trouble. Your doctor can compare it with the other drugs you take. Less time at a painful task may also settle a flare, so you needn't rush past what already helps.

If daily life remains hard, an exam can sort the choices

When soreness still limits sleep or movement, natural pain treatments are available from QC Kinetix. That phrase means non-surgical care the clinic prepares with material drawn from your blood, including concentrated PRP. Its medical providers are the clinicians who examine you and review any X-rays.

You can describe what relief would make walking, sleep, or chores easier. The clinician can explain when any change should be checked. An exam may also show that another treatment fits better, and you aren't expected to arrive with the answer.

Sources

1. The 2019 ACR/Arthritis Foundation osteoarthritis guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-management programmes, tai chi, cane use, tibiofemoral bracing, topical and oral NSAIDs and intra-articular glucocorticoid injections for knee OA. Its conditional recommendations cover balance exercises, yoga, CBT, acupuncture, thermal modalities, radiofrequency ablation, acetaminophen, duloxetine and tramadol. Anything offered before a course of the strongly recommended options is being offered out of order.

   Kolasinski SL, Neogi T, Hochberg MC, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. A meta-analysis of eight studies (648 patients, mean age 59) judged at low risk of bias found PRP significantly better than intra-articular corticosteroid for knee OA symptoms at 3, 6 and 9 months (P<0.01), with the largest effects at 6 months (SMD -0.78; 95% CI -1.34 to -0.23) and 9 months (SMD -1.63; 95% CI -2.14 to -1.12). This is the strongest available case for PRP as a longer-acting alternative to a steroid shot.

   McLarnon M, Heron N — Intra-articular platelet-rich plasma injections versus intra-articular corticosteroid injections for symptomatic management of knee osteoarthritis: systematic review and meta-analysis. BMC Musculoskeletal Disorders, 2021. DOI: 10.1186/s12891-021-04308-3.

4. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

5. A systematic review of 105 clinical PRP studies in orthopaedics published 2006-2016 found that only 11 (10%) described the preparation protocol clearly enough for another investigator to repeat it, and only 17 (16%) reported any quantitative metric of the final PRP composition. The authors concluded that the current reporting of PRP preparation and composition does not allow the PRP products actually delivered to patients to be compared between studies.

   Chahla J, Cinque ME, Piuzzi NS, et al. — A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. Journal of Bone and Joint Surgery (American), 2017. DOI: 10.2106/JBJS.16.01374.

6. A systematic review that screened 876 studies and extracted standardised data from 33 commercially available PRP systems and protocols found that final product concentrations of platelets, white cells and growth factors varied widely between systems, as did the preparation protocols themselves. Platelet concentration correlated directly with the volume of blood drawn and with the centrifugal force of the device. The authors called the heterogeneity between separation systems something that 'must be resolved for proper study of this promising treatment'.

   Fadadu PP, Mazzola AJ, Hunter CW, et al. — Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization. Regional Anesthesia and Pain Medicine, 2019. DOI: 10.1136/rapm-2018-100356.

7. A technical and biological review screened 1379 studies and identified 50 commercial PRP preparation systems in three technical categories (tubes, syringes, bags). Sufficient biological characterisation was available for only 14 of those 50 systems. Comparing the 36 characterised preparations across the seven existing PRP classifications revealed 'a large heterogeneity among the available current PRP commercial systems' and showed the classifications themselves differ in how well they discriminate between preparations.

   Magalon J, Brandin T, Francois P, et al. — Technical and biological review of authorized medical devices for platelets-rich plasma preparation in the field of regenerative medicine. Platelets, 2021. DOI: 10.1080/09537104.2020.1832653.

8. A systematic review of 132 Level I/II PRP studies across all medical specialties, covering 28 different conditions, found inconsistent reporting of PRP composition in every field of medicine. Musculoskeletal indications - knee osteoarthritis and tendinopathy above all - accounted for the majority of high-level studies. Sixty-one percent of the studies reported PRP as favourable over the control treatment, with no difference in that proportion between musculoskeletal and non-musculoskeletal specialties.

   Nazaroff J, Oyadomari S, Brown N, et al. — Reporting in clinical studies on platelet-rich plasma therapy among all medical specialties: A systematic review of Level I and II studies. PLOS ONE, 2021. DOI: 10.1371/journal.pone.0250007.

9. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis contains 29 recommendations, and the work group explicitly identified intra-articular corticosteroid, hyaluronic acid AND platelet-rich plasma as areas needing better research - including osteoarthritis characterisation, severity stratification, clinically relevant outcomes with controls for bias, and cost-effectiveness analysis. PRP is presented as an open research question in this guideline, not as a settled treatment.

   Brophy RH, Fillingham YA — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition. Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.